Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

LUCY Letby’s conviction risks being thrown wide open after medical experts deemed evidence used to convict her “unsafe”. Last ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Today in History for Feb. 11: ...

often used with injectable long-acting insulin Afrezza (inhaled insulin) Regular-/short-acting 30 minutes Three to six hours Usually taken 30 to 60 minutes before a meal Humulin R, Novolin R, ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.